Eli Lilly and Company — SEC Form 4 Filings
SEC Form 4 Data
Track insider buying and selling activity for Eli Lilly and Company (LLY). Data sourced from SEC EDGAR Form 4 filings and analyzed by StoxPulse AI for significance.
14
$135K total
6
$27.5M total
2.3x
Bullish Signal
20
Form 4 transactions
Buy − Sell value
Sale · May 6, 2026
Zakrowski · Sale
Eli Lilly and Company insiders filed 20 Form 4 transactions in the period analyzed: 14 purchases totaling $135K and 6 sales totaling $27.5M. That puts the buy-to-sell ratio at 2.33, which we read as bullish on a directional basis.
The most active filer was Sulzberger Gabrielle with 4 transactions in this window. 18 of the 20 filings are flagged as routine — typically 10b5-1 scheduled trades rather than discretionary signals.
Form 4 filings are point-in-time disclosures and do not constitute investment advice. Routine sales under pre-arranged 10b5-1 plans should not be read as bearish.
| Insider | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Zakrowski Donald A | SVP, Finance, & CAO | Sale | 2,000 | $1185.01 | $2.4M | 2026-08-10 |
| Hakim Anat | EVP, GC & Secretary | Sale | 5,000 | $1190.00 | $6.0M | 2026-08-07 |
| Seymour Melissa | EVP, Global Quality | Buy | 981 | $0.00 | $0.00 | 2026-08-01 |
| Seymour Melissa | EVP, Global Quality | Sale | 438.707 | $1148.84 | $504K | 2026-08-01 |
| Sulzberger Gabrielle | Director | Buy | 4.323 | $1146.90 | $5K | 2026-07-20 |
| LUCIANO JUAN R | Director | Buy | 13.878 | $1146.90 | $16K | 2026-07-20 |
| Fyrwald J Erik | Director | Buy | 8.647 | $1146.90 | $10K | 2026-07-20 |
| Alvarez Ralph | Director | Buy | 10.826 | $1146.90 | $12K | 2026-07-20 |
| Sulzberger Gabrielle | Director | Buy | 4.39 | $1129.35 | $5K | 2026-06-15 |
| LUCIANO JUAN R | Director | Buy | 14.094 | $1129.35 | $16K | 2026-06-15 |
| Fyrwald J Erik | Director | Buy | 8.781 | $1129.35 | $10K | 2026-06-15 |
| Alvarez Ralph | Director | Buy | 10.995 | $1129.35 | $12K | 2026-06-15 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab | Sale | 2,500 | $1150.77 | $2.9M | 2026-06-10 |
| Sulzberger Gabrielle | Director | Buy | 5.018 | $988.09 | $5K | 2026-05-18 |
| LUCIANO JUAN R | Director | Buy | 16.109 | $988.09 | $16K | 2026-05-18 |
| Fyrwald J Erik | Director | Buy | 10.036 | $988.09 | $10K | 2026-05-18 |
| Alvarez Ralph | Director | Buy | 12.566 | $988.09 | $12K | 2026-05-18 |
| LILLY ENDOWMENT INC | Former 10% Shareholder | Sale | 13,620 | $995.23 | $13.6M | 2026-05-06 |
| LILLY ENDOWMENT INC | Former 10% Shareholder | Sale | 2,208 | $996.18 | $2.2M | 2026-05-06 |
| Sulzberger Gabrielle | Director | Buy | 5.39 | $919.90 | $5K | 2026-04-20 |
Insider trading data for Eli Lilly and Company (LLY) is sourced directly from SEC Form 4 filings on the EDGAR database. Corporate insiders — including directors, officers, and shareholders owning more than 10% of the company — are legally required to report their transactions within two business days.
Insider purchases are often considered a bullish signal because executives are using their own money to buy shares, suggesting they believe the stock is undervalued. Insider sales, on the other hand, are more nuanced — they can reflect routine diversification plans (known as 10b5-1 plans), tax obligations, or genuine concerns about the company's outlook.
StoxPulse's AI system analyzes each LLY insider transaction to determine whether it appears routine or notable. We track the buy/sell ratio, total transaction values, and patterns over time to provide a clear picture of insider sentiment for Eli Lilly and Company.
AI earnings, financials, news & more
Translate any filing into plain English
Disclaimer: Insider trading data for Eli Lilly and Company (LLY) is sourced from SEC Form 4 filings and is provided for informational purposes only. Insider transactions should not be the sole basis for investment decisions. Always consult a qualified financial advisor.
Join the waitlist to receive instant AI notifications when Eli Lilly and Company insiders buy or sell shares.
Join the Waitlist